IBBQ:NSD-Invesco Nasdaq Biotechnology ETF (USD)

ETF | Others |

Last Closing

USD 21.94

Change

-0.32 (-1.44)%

Market Cap

USD 0.04B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-11 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
IBIT iShares Bitcoin Trust

+1.05 (+1.94%)

USD 59.02B
QQQM Invesco NASDAQ 100 ETF

+0.14 (+0.06%)

USD 42.88B
JEPQ JPMorgan Nasdaq Equity Premium..

N/A

USD 22.89B
ACWI iShares MSCI ACWI ETF

-0.11 (-0.09%)

USD 19.52B
CGABL The Carlyle Group Inc. 4.625% ..

-0.15 (-0.84%)

USD 16.14B
NVDL GraniteShares 1.5x Long NVDA D..

-1.57 (-2.64%)

USD 4.90B
TBIL Rbb Fund Inc - Us Treasury 3 M..

-0.01 (-0.02%)

USD 4.81B
TSLL Direxion Shares ETF Trust - Di..

+0.81 (+4.67%)

USD 4.32B
ETHA iShares Ethereum Trust ETF

+0.65 (+3.31%)

USD 3.75B
USCL iShares Climate Conscious & Tr..

-0.21 (-0.28%)

USD 2.37B

ETFs Containing IBBQ

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.95% 56% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.95% 56% F 57% F
Trailing 12 Months  
Capital Gain 1.86% 42% F 50% F
Dividend Return 0.85% 23% F 17% F
Total Return 2.71% 30% F 46% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 0.54% 45% F 40% F
Dividend Return 0.87% 40% F 36% F
Total Return 0.34% 25% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 12.05% 50% F 87% B+
Risk Adjusted Return 7.26% 35% F 39% F
Market Capitalization 0.04B 55% F 26% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.